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Tumor recurrence: a poorly understood 
phenomenon
Typically,  when  a  tumor  is  discovered,  patients  are 
treated with a combination of surgery, chemotherapy and 
radiotherapy,  depending  on  the  location  and  type  of 
cancer.  The  goal  of  these  treatments  is  to  completely 
remove or destroy any cancerous cell growth. Often these 
treatments are met with apparent success, as indicated by 
shrinkage  in  tumor  volume.  Tumor  reemergence  is, 
however,  frequent  [1]  but  this  phenomenon  is  poorly 
understood. It is not even clear whether one common 
factor underpins the ability of many different tumor types 
to reemerge after a remission period.
This general problem has led researchers to investigate 
possible explanations for tumor recurrence. One idea is 
that tumor heterogeneity is derived from a cell capable of 
generating many different cell types. This has led to the 
prediction that at least some tumors arise from a cell with 
stem-like properties. It is unclear, however, whether this 
would be a naturally occurring multipotent stem cell or a 
cell  that  acquires  stem-like  properties  following 
mutational events, for example. Although the origin of 
these stem-like cells is contentious, the term cancer stem 
cell (CSCs) is often applied and will be used here. CSCs 
are  currently  a  ‘hot’  topic  because  their  potential 
properties are consistent with a tumor-initiating cell that 
might be able to regenerate the complexity of an entire 
tumor [2]. The obvious question, however, is how CSCs 
could  survive  genotoxic  damage  under  conditions  in 
which other tumor cells die. The answer to this question 
could  be  crucial  for  the  development  of  new  tumor 
therapeutics.
Subpopulations with increased apoptotic 
resistance
Understanding the mechanisms underpinning resistance 
to apoptosis following chemo- or radiotherapy has been 
prompted by the promise that this could lead to a new 
generation  of  therapeutic  approaches.  Several  reports 
indicate that CSCs can pump out toxins through specific 
chemical  efflux  pathways  [3].  These  cells  are  often 
resistant to DNA damage and show greater DNA repair 
capacity than their non-stem-like counterparts [4]. New 
findings reported in BMC Cancer [5] reveal that altered 
cell cycle regulation could also have a role in apoptotic 
resistance in at least some CSCs.
Epithelial  tumors  are  the  most  commonly  diagnosed 
cancer type [6] and are therefore a high priority in terms 
of  therapeutic  development.  Mackenzie  and  colleagues 
[5] address the problem by focusing on human head and 
neck squamous cell carcinomas (HNSCCs). HNSCCs are 
epithelial tumors with a high rate of tumor recurrence 
following  initial  treatment  [7],  making  them  a  logical 
choice for investigation of apoptotic resistance mecha-
nisms.  As  in  previous  studies,  subpopulations  of  cells 
with stem-like properties were isolated by fluorescence-
activated cell sorting (FACS), using the cell surface glyco-
protein  CD44  as  a  marker.  Assays  comparing  in  vitro 
‘tumor sphere’ formation and clonogenicity demon  strated 
that cells expressing high levels of CD44 (CD44high) with a 
highly  compact,  holoclone  colony  morphology  have 
stem-like characteristics of CSCs.
Mackenzie and colleagues [5] show that CD44high cells 
are less sensitive to several chemical apoptosis-inducing 
agents than are CD44low cells. Although previous studies 
showed  that  ABC  transporters  are  expressed  at  high 
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chemicals  is  not  the  entire  story  when  it  comes  to 
apoptotic  resistance  [8].  The  current  study  [5],  for 
example, shows that treatment with chemotherapeutics 
and radiotherapy is less effective at promoting apoptosis 
in CD44high cells, thereby arguing against a role for ABC 
transporters.
Increased apoptotic resistance is associated with a 
G2/M phase cell cycle block
What, then, is the reason behind the observed apoptotic 
insensitivity in CD44high CSCs? Insight into this question 
came  from  observations  made  by  Mackenzie  and 
colleagues [5], who showed that CD44high subpopulations 
of epithelial, breast and prostate carcinoma cells have a 
consistently higher proportion of cells in the G2 phase. 
Using  pulse  chase  experiments  involving  5-iodo-2’-
deoxyuridine (IdU) labeling of cells in S phase followed 
by FACS analysis, cell cycle progression was then tracked 
through G2 back into G1. The conclusion of this study is 
that CD44high cells spent a consistently longer time in G2.
In normal cell types, DNA damage caused by chemi-
cals, radiation or faulty replication halts cellular progres-
sion by activating a cell cycle checkpoint at the G2/M 
boundary,  while  DNA  repair  mechanisms  restore 
genomic integrity. If the extent of damage is too great for 
repair mechanisms to correct, apoptosis is often induced 
[9]. Previous studies by Rich and colleagues [4] showed 
that glioblastoma cells are more resistant to radiotherapy 
than normal cells because they activate the DNA damage 
response.  Checkpoint  controls  are  implicated  in  this 
mecha  nism because inhibition of Chk1 and Chk2 check-
point kinases remove the resistance to radiotherapy. A 
similar effect was observed by Mackenzie and colleagues 
[5], who found that levels of phosphorylated Chk1 and 
Chk2 are consistently higher in CD44high subpopulations 
and  thus  greater  checkpoint  activation  is  achieved. 
Knockdown of Chk1 and Chk2 by chemical inhibition or 
by  small  interfering  RNA  targeting  in  CD44high 
subpopulations  led  to  a  decrease  in  the  percentage  of 
cells in G2 phase to a level comparable to that of CD44low 
cells. This provides further confirmation for a mechanism 
in which CD44high CSCs, with a prolonged G2 phase, are 
apoptosis-resistant  because  of  activated  checkpoints. 
Activating checkpoint controls in CSCs therefore seems 
to  impose  a  G2/M  blockade,  which  gives  a  selective 
advantage  in  terms  of  cell  survival  and  tumor-forming 
potential (Figure 1).
Future directions and therapeutic value
Mackenzie  and  colleagues  [5]  have  revealed  important 
additional information about the mechanisms by which 
tumors evade current therapeutic treatments. Of interest 
is the finding that CD44high subpopulations, displaying an 
Figure 1. Cancer stem cells (CSCs) escape apoptosis by upregulating G2/M checkpoint proteins, leading to a longer G2 phase and 
perhaps a longer window for DNA repair. Following chemo- or radiotherapy, all cells undergo DNA damage, but the extended G2 phase in CSCs 
means that they have more time to repair the damage and are thus more resistant to apoptosis.
Chemo- or
radiotherapy 
Repair fails 
Chk1/Chk2
upregulation,
extended G2 phase,
DNA repair 
Other tumor cells
(CD44low) 
CSCs
(CD44high) 
DNA
damage 
DNA
damage 
CSC
Heterogeneous
tumor population 
Tumor relapse/
proliferation
Apoptosis
Chappell and Dalton BMC Biology 2010, 8:63 
http://www.biomedcentral.com/1741-7007/8/63
Page 2 of 3increase in apoptotic resistance and a longer G2 phase, 
were  also  found  in  normal  oral  keratinocytes.  This 
observation is a strong argument for the idea that a small 
subpopulation of cells with inherent stem-like properties 
naturally occurs and is not solely a product of malignant 
transformation.
More importantly, the authors [5] demonstrate that in 
addition to the efficient efflux and DNA repair mecha-
nisms,  CSCs  also  have  an  altered  cell  cycle  program. 
Further biochemical characterization of these cells may 
explain  how  the  G2/M  checkpoint  is  activated  and 
exactly how a longer G2 phase is conferring a survival 
advantage in cooperation with previously known mecha-
nisms. A key question is what signaling pathways activate 
checkpoints in CD44high cells. This could provide insight 
into  what  should  be  targeted  for  drug  development. 
Prematurely  releasing  these  cells  from  their  prolonged 
G2 phase and G2/M block could trigger apoptosis instead 
of enhanced survival and tumor relapse. Therefore, it may 
be  advantageous  for  future  therapeutic  treatments  to 
target the Chk proteins or their upstream activators. In 
combination  with  modern  chemical  or  radiation-based 
therapies,  tumor  elimination  without  relapse  is  an 
exciting possibility.
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